ATXS - NASDAQ
Astria Therapeutics, Inc.
$12.58
+0.0000%Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
At a Glance
Live SnapshotAstria Therapeutics, Inc. Management Team
Ms. Andrea L. Matthews
Chief Business Officer
Mr. Andrew A. Komjathy
Chief Commercial Officer
Mr. Noah C. Clauser CPA
Chief Financial Officer & Treasurer
Compensation
$621,406
Ms. Keri McGrail
Chief Human Resources Officer
Mr. Benjamin S. Harshbarger J.D.
Chief Legal Officer
Compensation
$658,041
Dr. Christopher J. Morabito M.D.
Chief Medical Officer
Compensation
$690,824
Ms. Jill C. Milne Ph.D.
Co-Founder, Chief Executive Officer, President & Director
Compensation
$967,338
Ms. Rafif Dagher
Senior Vice President and Head of Discovery, Nonclinical Development & Translational Research
Mr. John Ruesch
Senior Vice President of Pharmaceutical Sciences & Technical Operations
Astria Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.23M worth of ATXS shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
212.4K
1.23M
0
0.00
+1.2M
+$1.23M
Top Buyers
Agarwal Sunil
Director
$154K
Bate Kenneth
Director
$154K
Cole Hugh M
Director
$154K
Kishbauch Michael D
Director
$154K
Lapointe Anthony Gregg
Director
$154K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $1.23M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
ATXS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 22, 2024 | June 05, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 20, 2023 | April 20, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 09, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | November 04, 2021 | December 14, 2021 | 2021 | |
DEF 14A DEF 14A 2021 N/A | April 16, 2021 | June 02, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 28, 2020 | June 11, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 22, 2019 | June 04, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | October 23, 2018 | December 12, 2018 | 2018 | |
DEF 14A DEF 14A 2018 N/A | April 26, 2018 | June 07, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.